mRNA企业正站在肿瘤治疗的舞台中央。BioNTech全力押注下一代肿瘤免疫疗法(IO, Immuno-Oncology),以mRNA疫苗为基本盘,在双抗、细胞疗法等领域重兵布局,这也让资本市场对其预期发生大幅扭转。曾几何时,老对手Moderna的市值是BioNTech的3倍;但眼下,BioNTech完成大逆转,以267亿美元的市值稳坐mRNA领域头把交椅。而Moderna因在预防性疫苗领域接连...
Source LinkmRNA企业正站在肿瘤治疗的舞台中央。BioNTech全力押注下一代肿瘤免疫疗法(IO, Immuno-Oncology),以mRNA疫苗为基本盘,在双抗、细胞疗法等领域重兵布局,这也让资本市场对其预期发生大幅扭转。曾几何时,老对手Moderna的市值是BioNTech的3倍;但眼下,BioNTech完成大逆转,以267亿美元的市值稳坐mRNA领域头把交椅。而Moderna因在预防性疫苗领域接连...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.